Table 6.
Summary of trials addressing systemic therapy in advanced breast cancer
| Author, year | Institution(s)/ Database | Population | Time intervals | Comments |
|---|---|---|---|---|
| Andre, 2004
[5] |
France (3 institutions) |
724 women de novo metastatic breast cancer |
1987-1993 |
Excluded supraclavicular lymph node only patients. Improved 3 year overall survival (OS; 44% vs 27%) was seen in the more recent time period. |
| |
|
|
1994-2000 |
|
| Giordano, 2004
[9] |
MD Anderson Cancer Center |
834 women with recurrence after adjuvant doxorubicin |
1974-1979 |
Included patients with locally recurrent disease. Predictors of improved overall survival included stage at diagnosis, interval disease-free survival, and dominant metastatic site. |
| |
|
|
1980-1984 |
|
| |
|
|
1985-1989 |
|
| |
|
|
1990-1994 |
|
| |
|
|
1995-2000 |
|
| Chia, 2007
[6] |
British Columbia Cancer Agency |
2150 women with both recurrent and de novo metastatic breast cancer |
1991-1992 |
An improvement in overall survival was noted over time, primarily in those patients that were hormone-receptor positive. |
| |
|
|
1994-1995 |
|
| |
|
|
1997-1998 |
|
| |
|
|
1999-2001 |
|
| Dawood, 2008
[13] |
Surveillance, Epidemiology, and End Results Registry |
15,438 women with both recurrent and de novo metastatic breast cancer |
1988-1993 |
There was a modest improvement in overall survival, associated with patients with hormone-receptor positive disease. Outcomes appeared to be worse in African American women. |
| |
|
|
1994-1998 |
|
| |
|
|
1999-2002 |
|
| |
|
|
2003-2006 |
|
| Dafni, 2009
[14] |
Hellenic Cooperative Group |
1361 enrolled on trials for treatment of recurrent and de novo metastatic breast cancer |
1991-1994 |
Trastuzumab used in 24% and 30% of patients in the two most recent time intervals. |
| |
|
|
1995-1998 |
|
| |
|
|
1999-2003 |
|
| Ruiterkamp, 2011
[10] |
Netherlands |
8031 women with both recurrent and de novo metastatic breast cancer |
1995-1999 |
10% of patients in third time interval received targeted therapy. |
| |
|
|
2000-2004 |
|
| |
|
|
2005-2008 |
|
| Pal, 2011 |
City of Hope |
274 de novo metastatic breast cancer only |
1985-1994 |
Overall survival improved for those receiving endocrine therapy, but no apparent overall survival benefit with newer chemotherapeutic agents. |
| 1995-2004 |